Clinical Trial

Model-Informed Precision Dosing on Cyclosporine Therapy in Hematopoietic Stem Cell Transplant Recipients

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to develop a new tool that helps doctors choose the right cyclosporine dose for patients undergoing bone marrow transplantation. The tool is designed to predict the best dose using sparse sampling, making it practical for everyday clinical care. It combines information about population pharmacokinetics of cyclosporine with advanced artificial intelligence techniques, including machine learning and deep learning. This tool aims to improve treatment, personalize dosing for each patient, and reduce the risk of graft-versus-host disease.
Trial Details
NCT Number NCT07695571
Lead Sponsor Yasmin medhat munir Mohamed
Conditions Bone Marrow Transplantation, AML
Enrollment 300 participants
Start Date 2026-08-01
Primary Completion 2027-01-01 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-10